First-in-Class Innovation In Parkinson’s Disease Market

1
Frontier Pharma Parkinsons Disease -
Identifying and Commercializing First-in-Class
Innovation
2
Summary
Large Degree of Innovation in Parkinsons Disease
Pipeline The Parkinsons disease (PD) pipeline
currently has 302 products in active development
across all stages, but a stark contrast between
the mechanisms of action employed in the current
market and the pipeline is evident. Where the
market relies on symptomatic treatments that
target neuromodulatory receptors, the pipeline
shows a diverse range of neuroprotective
therapies targeting dysfunctional disease
processes. This diversity is partially due to
the presence of 90 first-in-class products, which
accounts for 37 of the overall pipeline
therapies that disclosed their target. In an
industry, market and development landscape that
favors first-in-class over non-first-in-class
development in many ways, such as through faster
approval or greater revenue, this finding has
strategic implications for a wide array of market
participants, both large and small. Despite their
historically high attrition rate, first-in-class
therapies that reach the market have the
potential to transform and improve the PD
treatment landscape. For Further Details
http//www.bigmarketresearch.com/frontier-pharma-p
arkinsons-disease-identifying-and-commercializing-
first-in-class-innovation-market
3
Report Description
Alignment of First-in-Class Molecular Target with
Disease Processes and Genetics PD is a complex
and multifaceted disease with a complex interplay
between different pathological processes.
Enormous research efforts and significant
technological advances have furthered knowledge
of the neuroanatomy of the basal ganglia and of
the fundamental processes underlying
neurodegeneration, helped by the ongoing
identification of susceptibility genes and
causative genes in familial PD. Although the
exact mechanisms that initiate onset remain
unclear, these insights have been translated into
the pool of novel therapeutic targets, which may
potentially become disease-modifying therapies by
aligning to the disease processes and some
genetic determinants of PD. GBI Researchs
proprietary analysis showed substantial variation
in how well the functional roles of PD
first-in-class targets align to the
pathophysiology of PD. Further in-depth analysis
identified the most promising first-in-class
targets based on various scientific and clinical
parameters. Examining scientific and clinical
data of promising first-in-class targets showed
that first-in-class status is not, in its own
right, enough for a successful product however,
the first-in-class products substantiated by
scientific and clinical evidence will be exciting
future prospects with the potential to transform
the PD market.
4
Key Segment
First-in-Class Products in Licensing and
Co-development Deals Strategic consolidation is
relatively uncommon in the PD market. Concerning
first-in-class specifically, only nine
first-in-class products that are currently in
development have been involved in licensing or
co-development deals since 2006. Despite the low
sample size, it is clear that the first-in-class
PD products offer an attractive investment
prospect as they command much higher deal values
and, on average, deals occur earlier in
development compared to non-first-in-class
counterparts. Both trends were substantiated by
industry-wide data that showed that, particularly
in Phase I, first-in-class products would attract
larger mean and median total deal values. The
data highlight that the first-in-class deals
landscape is different and indicates a greater
chance of becoming much more lucrative than the
deals landscape for addition-to-class or
advance-in-class therapies. A total of 81
first-in-class products that are currently in
development have not yet been entered into a
licensing or co-development deal. Under a growing
unmet need for disease-modifying therapies and
increasing understanding of disease processes
allowed by technological advances, there are
numerous opportunities for strategic alliances to
bolster a first-in-class portfolio or fund
clinical development. Some of these
first-in-class products are supported by
promising scientific and clinical data, making
them attractive prospects as both therapeutics
and investment opportunities.
5
Scope

• The report analyzes innovation in PD in the
  context of the overall pipeline and current
  market landscape. It also analyzes the deals
  landscape surrounding first-in-class products and
  pinpoints in-licensing opportunities.The report
  includes -
• A brief introduction to PD, including symptoms,
  pathophysiology, and an overview of
  pharmacotherapy and treatment algorithms
• Coverage of the changing molecular target
  landscape and particular points of innovation in
  the pipeline
• A comprehensive review of the pipeline for
  first-in-class therapies, analyzed by stage of
  development, molecule type and molecular target.
• Identification and assessment of first-in-class
  molecular targets with a particular focus on
  early-stage programs of which clinical utility
  has yet to be evaluated, as well as literature
  reviews of novel molecular targets
• Industry-wide analysis of first-in-class deals
  compared to non-first-in-class deals
• An assessment of the licensing and co-development
  deal landscape for PD therapies and benchmarking
  of deals comparing first-in-class and
  non-first-in-class-products
• Read The Complete Report On http//www.bigmarket
  research.com/frontier-pharma-parkinsons-disease-id
  entifying-and-commercializing-first-in-class-innov
  ation-market

6
Reasons to buy

• The report will enable business development and
  enable marketing executives to strategize their
  product launches by allowing them to -
• Understand the focal shifts in molecular targets
  in the PD pipeline
• Understand the distribution of pipeline programs
  by phase of development, molecule type and
  molecular target
• Access a scientific and clinical analysis of
  first-in-class developmental programs for PD,
  benchmarked against non-first-in-class targets
• Assess the valuations of licensed and
  co-developed PD treatments
• Access a list of the first-in-class therapies
  potentially open to deal-making opportunities
• To Get More Details Enquire _at_ http//www.bigmarket
  research.com/report-enquiry/170666

7
Content

1. Executive Summary
2. The Case for Innovation
3. Clinical and Commercial Landscape
4. Assessment of Pipeline Product Innovation
5. Signaling Network, Parkinsons Disease Genetics
   and Innovation Alignment
6. First-in-Class Target and Pipeline Program
   Evaluation
7. Deals and Strategic Consolidations
8. Appendix
9. Read The Complete TOC _at_ http//www.bigmarketresear
   ch.com/frontier-pharma-parkinsons-disease-identify
   ing-and-commercializing-first-in-class-innovation-
   market

8
Contact Us
Deep Joshi 5933 NE Win Sivers Drive, 205,
Portland, OR 97220 United States Direct 1
[phone] Toll Free 1 [phone] Fax
1 [phone] Email help_at_bigmarketresearch
.com Web http//www.bigmarketresearch.com